Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.


Journal

Acta crystallographica. Section F, Structural biology communications
ISSN: 2053-230X
Titre abrégé: Acta Crystallogr F Struct Biol Commun
Pays: United States
ID NLM: 101620319

Informations de publication

Date de publication:
01 Dec 2021
Historique:
received: 03 09 2021
accepted: 04 11 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 5 4 2022
Statut: ppublish

Résumé

Eukaryotic protein kinases contain an Asp-Phe-Gly (DFG) motif, the conformation of which is involved in controlling the catalytic activity, at the N-terminus of the activation segment. The motif can be switched between active-state (DFG-in) and inactive-state (DFG-out) conformations: however, the mechanism of conformational change is poorly understood, partly because there are few reports of the DFG-out conformation. Here, a novel crystal structure of nonphosphorylated human mitogen-activated protein kinase kinase 1 (MEK1; amino acids 38-381) complexed with ATP-γS is reported in which MEK1 adopts the DFG-out conformation. The crystal structure revealed that the structural elements (the αC helix and HRD motif) surrounding the active site are involved in the formation/stabilization of the DFG-out conformation. The ATP-γS molecule was bound to the canonical ATP-binding site in a different binding mode that has never been found in previously determined crystal structures of MEK1. This novel ATP-γS binding mode provides a starting point for the design of high-affinity inhibitors of nonphosphorylated inactive MEK1 that adopts the DFG-out conformation.

Identifiants

pubmed: 34866601
pii: S2053230X21011687
doi: 10.1107/S2053230X21011687
pmc: PMC8647213
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Protein Kinases EC 2.7.-
MAP Kinase Kinase 1 EC 2.7.12.2
MAP2K1 protein, human EC 2.7.12.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-464

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 26440035
Organisme : Japan Agency for Medical Research and Development
ID : JP21am0101111

Références

Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Annu Rev Biochem. 2012;81:587-613
pubmed: 22482904
Annu Rev Biochem. 2011;80:769-95
pubmed: 21548788
Biochem Biophys Res Commun. 2012 Jan 6;417(1):5-10
pubmed: 22177953
Cell. 2003 Mar 21;112(6):859-71
pubmed: 12654251
Biochem J. 2000 Oct 15;351 Pt 2:289-305
pubmed: 11023813
Trends Biochem Sci. 2011 Feb;36(2):65-77
pubmed: 20971646
Cell. 1996 Apr 19;85(2):149-58
pubmed: 8612268
J Phys Chem A. 2009 Nov 19;113(46):12763-73
pubmed: 19831376
J Med Chem. 2010 Apr 8;53(7):2681-94
pubmed: 20000735
Nat Struct Mol Biol. 2004 Dec;11(12):1192-7
pubmed: 15543157
Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17783-8
pubmed: 17095602
Eur J Med Chem. 2021 Jun 5;218:113386
pubmed: 33774345
ACS Med Chem Lett. 2012 Apr 09;3(5):416-21
pubmed: 24900486
Biochemistry. 2009 Mar 31;48(12):2661-74
pubmed: 19161339
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Nat Rev Cancer. 2015 Oct;15(10):577-92
pubmed: 26399658
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Biol Chem. 1993 May 25;268(15):11435-9
pubmed: 8388392
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Chem Rev. 2001 Aug;101(8):2271-90
pubmed: 11749373
Biochemistry. 2007 Feb 6;46(5):1358-67
pubmed: 17260965
FASEB J. 1995 Jun;9(9):726-35
pubmed: 7601337

Auteurs

Setsu Nakae (S)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Maho Kitamura (M)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Daisuke Fujiwara (D)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Masaaki Sawa (M)

Carna Biosciences Inc., BMA 3F 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan.

Tsuyoshi Shirai (T)

Department of Bioscience, Nagahama Institute of Bio-Science and Technology, 1266 Tamura, Nagahama 526-0829, Japan.

Ikuo Fujii (I)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Toshiji Tada (T)

Graduate School of Science, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8531, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH